Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

John D. Imig PhD

John D. Imig PhD

Professor

Institution: Medical College of Wisconsin
Department: Pharmacology and Toxicology
Program: Program Development


Publications

  • Azilsartan Improves Glycemic Status and Reduces Kidney Damage in Zucker Diabetic Fatty Rats. (Hye Khan MA, Neckár J, Haines J, Imig JD) Am J Hypertens 2014 Mar 11: PMID 24598210
  • Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. (Kujal P, Certíková Chábová V, Skaroupková P, Husková Z, Vernerová Z, Kramer HJ, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kitada K, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Cervenka L) Clin Exp Pharmacol Physiol 2014 Mar;41(3):227-37 PMID 24471737
  • Fructose stimulates Na/H exchange activity and sensitizes the proximal tubule to angiotensin II. (Cabral PD, Hong NJ, Hye Khan MA, Ortiz PA, Beierwaltes WH, Imig JD, Garvin JL) Hypertension 2014 Mar;63(3):e68-73 PMID 24379189
  • The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. (Capdevila JH, Pidkovka N, Mei S, Gong Y, Falck JR, Imig JD, Harris RC, Wang W) J Biol Chem 2014 Feb 14;289(7):4377-86 PMID 24368771
  • Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. (Mohamed IN, Hafez SS, Fairaq A, Ergul A, Imig JD, El-Remessy AB) Diabetologia 2014 Feb;57(2):413-23 PMID 24201577
  • Afferent Arteriolar Responses to β,γ-methylene ATP and 20-HETE are not Blocked by ENaC Inhibition. (Nagasawa T, Imig JD) Physiol Rep 2013 Sep 1;1(4):e00082 PMID 24159379
  • Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. (Hye Khan MA, Neckár J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, Falck JR, Imig JD) Hypertension 2013 Nov;62(5):905-13 PMID 23980070
  • Immune and inflammatory role in renal disease. (Imig JD, Ryan MJ) Compr Physiol 2013 Apr;3(2):957-76 PMID 23720336
  • Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. (Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD) J Cardiovasc Pharmacol 2013 Sep;62(3):285-97 PMID 23676336
  • Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. (Khan MA, Liu J, Kumar G, Skapek SX, Falck JR, Imig JD) FASEB J 2013 Aug;27(8):2946-56 PMID 23603837
  • Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats. (Imig JD, Walsh KA, Hye Khan MA, Nagasawa T, Cherian-Shaw M, Shaw SM, Hammock BD) Exp Biol Med (Maywood) 2012 Dec;237(12):1402-12 PMID 23354399
  • Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. (Imig JD) Prostaglandins Other Lipid Mediat 2013 Jul-Aug;104-105:2-7 PMID 23333581
  • Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. (Honetschlägerová Z, Kitada K, Husková Z, Sporková A, Kopkan L, Bürgelová M, Varcabová Š, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerová Z, Červenka L) J Hypertens 2013 Feb;31(2):321-32 PMID 23307303
  • Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. (Varcabova S, Huskova Z, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Kitada K, Cervenka L) Clin Exp Pharmacol Physiol 2013 Apr;40(4):273-81 PMID 23039246
  • Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. (Kopkan L, Husková Z, Sporková A, Varcabová Š, Honetschlägerová Z, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Kramer HJ, Bürgelová M, Vojtíšková A, Kujal P, Vernerová Z, Červenka L) Kidney Blood Press Res 2012;35(6):595-607 PMID 22948718
  • Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. (Nagasawa T, Hye Khan MA, Imig JD) Clin Exp Pharmacol Physiol 2012 May;39(5):454-61 PMID 22443474
  • Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. (Neckář J, Kopkan L, Husková Z, Kolář F, Papoušek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Malý J, Netuka I, Ošťádal B, Červenka L) Clin Sci (Lond) 2012 Jun;122(11):513-25 PMID 22324471
  • 11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries. (Bukhari IA, Shah AJ, Gauthier KM, Walsh KA, Koduru SR, Imig JD, Falck JR, Campbell WB) Am J Physiol Heart Circ Physiol 2012 Apr 15;302(8):H1574-83 PMID 22307677
  • Epoxides and soluble epoxide hydrolase in cardiovascular physiology. (Imig JD) Physiol Rev 2012 Jan;92(1):101-30 PMID 22298653
  • Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. (Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD) Am J Physiol Regul Integr Comp Physiol 2011 Nov;301(5):R1307-17 PMID 21832210
  • Glomerular expression of kidney injury molecule-1 and podocytopenia in diabetic glomerulopathy. (Zhao X, Zhang Y, Li L, Mann D, Imig JD, Emmett N, Gibbons G, Jin LM) Am J Nephrol 2011;34(3):268-80 PMID 21822010
  • Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. (Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB) Am J Physiol Renal Physiol 2011 Oct;301(4):F765-72 PMID 21753077
  • Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. (Honetschlägerová Z, Sporková A, Kopkan L, Husková Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerová Z, Chábová VC, Tesař V, Cervenka L) J Hypertens 2011 Aug;29(8):1590-601 PMID 21720266
  • Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. (Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD) Proc Natl Acad Sci U S A 2011 May 31;108(22):9038-43 PMID 21571638
  • Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. (Khan AH, Imig JD) Am J Hypertens 2011 Jul;24(7):816-21 PMID 21415842
  • Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. (Sporková A, Kopkan L, Varcabová S, Husková Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Cervenka L) Am J Physiol Regul Integr Comp Physiol 2011 Jun;300(6):R1468-75 PMID 21411763
  • Cytochrome P450 eicosanoids and cerebral vascular function. (Imig JD, Simpkins AN, Renic M, Harder DR) Expert Rev Mol Med 2011;13:e7 PMID 21356152
  • Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. (Honetschlägerová Z, Z Husková Z, Vaňourková Z, Sporková A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Červenka L, Kopkan L) J Physiol 2011 Jan 1;589(Pt 1):207-19 PMID 21078594
  • 20-hydroxyeicosatetraenoic acid and angiotensin: a positive feedback system to cause hypertension. (Imig JD) Hypertension 2010 Nov;56(5):822-3 PMID 20837886
  • Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. (Pavlov TS, Imig JD, Staruschenko A) PPAR Res 2010;2010:703735 PMID 20613963
  • Targeting epoxides for organ damage in hypertension. (Imig JD) J Cardiovasc Pharmacol 2010 Oct;56(4):329-35 PMID 20531214
  • Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. (Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC) FASEB J 2010 Oct;24(10):3770-81 PMID 20495177
  • Epoxyeicosatrienoic acid analogs and vascular function. (Sudhahar V, Shaw S, Imig JD) Curr Med Chem 2010;17(12):1181-90 PMID 20158473
  • Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. (Certíková Chábová V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerová Z, Vanourková Z, Kopkan L, Kramer HJ, Falck JR, Imig JD, Hammock BD, Vanecková I, Cervenka L) Clin Sci (Lond) 2010 May;118(10):617-32 PMID 20050826
  • Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. (Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR) Front Physiol 2010;1:157 PMID 21423396
  • Soluble epoxide hydrolase inhibition modulates vascular remodeling. (Simpkins AN, Rudic RD, Roy S, Tsai HJ, Hammock BD, Imig JD) Am J Physiol Heart Circ Physiol 2010 Mar;298(3):H795-806 PMID 20035028
  • Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. (Walkowska A, Skaroupková P, Husková Z, Vanourková Z, Chábová VC, Tesar V, Kramer HJ, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Cervenka L) J Hypertens 2010 Mar;28(3):582-93 PMID 19940786
  • Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. (Knight SF, Yuan J, Roy S, Imig JD) Am J Physiol Renal Physiol 2010 Jan;298(1):F86-94 PMID 19906952
  • Adenosine2A receptors and epoxyeicosatrienoic acids: a recipe for salt and blood pressure regulation. (Imig JD) Hypertension 2009 Dec;54(6):1223-5 PMID 19822801
  • Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. (Imig JD, Hammock BD) Nat Rev Drug Discov 2009 Oct;8(10):794-805 PMID 19794443
  • Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. (Elmarakby AA, Imig JD) Clin Sci (Lond) 2010 Feb;118(4):291-301 PMID 19728860
  • Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. (Quigley R, Chakravarty S, Zhao X, Imig JD, Capdevila JH) Nephron Physiol 2009;113(4):p23-8 PMID 19713718
  • Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. (Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD) Am J Physiol Renal Physiol 2009 Sep;297(3):F740-8 PMID 19553349
  • Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. (Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD) Am J Pathol 2009 Jun;174(6):2086-95 PMID 19435785
  • Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. (Sudhahar V et al.) Eur J Pharmacol 2009 Apr 1;607(1-3):143-150 PMID 19374826
  • Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. (Sudhahar V, Shaw S, Imig JD) Eur J Pharmacol 2009 Apr 1;607(1-3):143-50 PMID 19326479
  • Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension. (Quigley JE, Elmarakby AA, Knight SF, Manhiani MM, Stepp DW, Olearzcyk JJ, Imig JD) Clin Exp Pharmacol Physiol 2009 Jul;36(7):724-8 PMID 19207724
  • SPARC ameliorates ovarian cancer-associated inflammation. (Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K) Neoplasia 2008 Oct;10(10):1092-104 PMID 18813349
  • Increased blood pressure in mice lacking cytochrome P450 2J5. (Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, Imig JD, Pedersen TL, Newman JW, Hammock BD, Conley AJ, Korach KS, Coffman TM, Zeldin DC) FASEB J 2008 Dec;22(12):4096-108 PMID 18716027
  • Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. (Chen JK, Chen J, Imig JD, Wei S, Hachey DL, Guthi JS, Falck JR, Capdevila JH, Harris RC) J Biol Chem 2008 Sep 5;283(36):24514-24 PMID 18606824
  • Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. (Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD) Clin Sci (Lond) 2009 Jan;116(1):61-70 PMID 18459944
  • Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels. (Imig JD, Dimitropoulou C, Reddy DS, White RE, Falck JR) Microcirculation 2008 Feb;15(2):137-50 PMID 18260004
  • Eicosanoids and renal damage in cardiometabolic syndrome. (Imig JD) Expert Opin Drug Metab Toxicol 2008 Feb;4(2):165-74 PMID 18248310
  • Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. (Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD) Hypertension 2008 Feb;51(2):352-9 PMID 18158349
  • TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. (Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM) Am J Physiol Regul Integr Comp Physiol 2008 Jan;294(1):R76-83 PMID 17989143
  • Normalization of the ovarian cancer microenvironment by SPARC. (Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K) Mol Cancer Res 2007 Oct;5(10):1015-30 PMID 17951402
  • Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. (Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, Inscho EW, Pollock DM, Imig JD) Hypertension 2007 Dec;50(6):1069-76 PMID 17938380
  • The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. (Certíková Chábová V, Kramer HJ, Vanecková I, Thumová M, Skaroupková P, Tesar V, Falck JR, Imig JD, Cervenka L) Kidney Blood Press Res 2007;30(5):335-46 PMID 17785988
  • Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. (Socha MJ, Manhiani M, Said N, Imig JD, Motamed K) Am J Pathol 2007 Oct;171(4):1104-12 PMID 17717147
  • Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. (Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD) J Clin Invest 2007 Sep;117(9):2496-505 PMID 17710229
  • Obesity, insulin resistance, and renal function. (Knight SF, Imig JD) Microcirculation 2007 Jun-Jul;14(4-5):349-62 PMID 17613807
  • Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. (Chábová VC, Kramer HJ, Vanecková I, Vernerová Z, Eis V, Tesar V, Skaroupková P, Thumová M, Schejbalová S, Husková Z, Vanourková Z, Kolský A, Imig JD, Cervenka L) Vascul Pharmacol 2007 Aug-Sep;47(2-3):145-59 PMID 17604232
  • Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. (Capdevila JH, Falck JR, Imig JD) Kidney Int 2007 Sep;72(6):683-9 PMID 17597703
  • IL6 suppression provides renal protection independent of blood pressure in a murine model of salt-sensitive hypertension. (Manhiani MM, Quigley JE, Socha MJ, Motamed K, Imig JD) Kidney Blood Press Res 2007;30(4):195-202 PMID 17575466
  • Novel nitric oxide synthase--dependent mechanism of vasorelaxation in small arteries from hypertensive rats. (Kang KT, Sullivan JC, Sasser JM, Imig JD, Pollock JS) Hypertension 2007 Apr;49(4):893-901 PMID 17309950
  • Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. (Dimitropoulou C, West L, Field MB, White RE, Reddy LM, Falck JR, Imig JD) Prostaglandins Other Lipid Mediat 2007 Feb;83(1-2):50-61 PMID 17259072
  • Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. (Elmarakby AA, Williams JM, Imig JD, Pollock JS, Pollock DM) Vascul Pharmacol 2007 Feb;46(2):144-51 PMID 17112788
  • Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. (Imig JD) Cardiovasc Drug Rev 2006;24(2):169-88 PMID 16961727
  • Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. (Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD) J Pharmacol Exp Ther 2006 Sep;318(3):1307-14 PMID 16772540
  • Eicosanoids and renal vascular function in diseases. (Imig JD) Clin Sci (Lond) 2006 Jul;111(1):21-34 PMID 16764555
  • Increased renal vascular reactivity to ANG II after unilateral nephrectomy in the rat involves 20-HETE. (Joly E, Seqqat R, Flamion B, Caron N, Michel A, Imig JD, Kramp R) Am J Physiol Regul Integr Comp Physiol 2006 Oct;291(4):R977-86 PMID 16675634
  • Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. (Jin L, Ying Z, Hilgers RH, Yin J, Zhao X, Imig JD, Webb RC) J Pharmacol Exp Ther 2006 Jul;318(1):288-95 PMID 16569756
  • PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. (Zhao X, Quigley JE, Yuan J, Wang MH, Zhou Y, Imig JD) Am J Physiol Heart Circ Physiol 2006 Jun;290(6):H2187-95 PMID 16501022
  • Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. (Elmarakby AA, Quigley JE, Pollock DM, Imig JD) Hypertension 2006 Mar;47(3):557-62 PMID 16415373
  • Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. (Jin L, Foss CE, Zhao X, Mills TM, Wang MH, McCluskey LP, Yaddanapud GS, Falck JR, Imig JD, Webb RC) FASEB J 2006 Mar;20(3):539-41 PMID 16415108
  • An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. (Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD) J Cardiovasc Pharmacol 2005 Dec;46(6):842-8 PMID 16306811
  • Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. (Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW) Am J Physiol Heart Circ Physiol 2006 Mar;290(3):H935-40 PMID 16284237
  • Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. (Portik-Dobos V, Harris AK, Song W, Hutchinson J, Johnson MH, Imig JD, Pollock DM, Ergul A) Am J Physiol Regul Integr Comp Physiol 2006 Feb;290(2):R435-41 PMID 16239374
  • ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. (Inscho EW, Imig JD, Cook AK, Pollock DM) Br J Pharmacol 2005 Dec;146(7):1019-26 PMID 16231007
  • An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. (Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD) Hypertension 2005 Oct;46(4):975-81 PMID 16157792
  • Impaired Ca2+ signaling attenuates P2X receptor-mediated vasoconstriction of afferent arterioles in angiotensin II hypertension. (Zhao X, Cook AK, Field M, Edwards B, Zhang S, Zhang Z, Pollock JS, Imig JD, Inscho EW) Hypertension 2005 Sep;46(3):562-8 PMID 16116048
  • Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. (Imig JD) Am J Physiol Renal Physiol 2005 Sep;289(3):F496-503 PMID 16093425
  • Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. (Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM) Hypertension 2005 Aug;46(2):366-71 PMID 15967866
  • Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. (Fuller AJ, Hauschild BC, Gonzalez-Villalobos R, Awayda MS, Imig JD, Inscho EW, Navar LG) Am J Physiol Renal Physiol 2005 Oct;289(4):F760-7 PMID 15942047
  • CYP450, COX-2 and Obesity Related Renal Damage. (Imig JD, Zhao X, Dey A, Shaw M) Toxicol Mech Methods 2005;15(2):125-36 PMID 20021073
  • L-type calcium channels in the renal microcirculatory response to endothelin. (Pollock DM, Jenkins JM, Cook AK, Imig JD, Inscho EW) Am J Physiol Renal Physiol 2005 Apr;288(4):F771-7 PMID 15547114
  • Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. (Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD) Am J Physiol Regul Integr Comp Physiol 2005 Jan;288(1):R188-96 PMID 15345471
  • Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. (Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, Imig JD) Obes Res 2004 Aug;12(8):1278-89 PMID 15340111
  • P2X receptor-stimulated calcium responses in preglomerular vascular smooth muscle cells involves 20-hydroxyeicosatetraenoic acid. (Zhao X, Falck JR, Gopal VR, Inscho EW, Imig JD) J Pharmacol Exp Ther 2004 Dec;311(3):1211-7 PMID 15316085
  • Rofecoxib decreases renal injury in obese Zucker rats. (Dey A, Maric C, Kaesemeyer WH, Zaharis CZ, Stewart J, Pollock JS, Imig JD) Clin Sci (Lond) 2004 Dec;107(6):561-70 PMID 15307815
  • Renal autoregulation in P2X1 knockout mice. (Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ) Acta Physiol Scand 2004 Aug;181(4):445-53 PMID 15283757
  • 20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis? (Imig JD) Am J Physiol Regul Integr Comp Physiol 2004 Jul;287(1):R3-5 PMID 15191921
  • Age-related alterations in NOS and oxidative stress in mesenteric arteries from male and female rats. (Sullivan JC, Loomis ED, Collins M, Imig JD, Inscho EW, Pollock JS) J Appl Physiol (1985) 2004 Oct;97(4):1268-74 PMID 15169747
  • Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. (Inscho EW, Cook AK, Murzynowski JB, Imig JD) J Hypertens 2004 Apr;22(4):811-8 PMID 15126924
  • Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. (Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD) J Am Soc Nephrol 2004 May;15(5):1244-53 PMID 15100364
  • ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement. (Imig JD) Hypertension 2004 Mar;43(3):533-5 PMID 14757781
  • Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. (Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ) J Clin Invest 2003 Dec;112(12):1895-905 PMID 14679185
  • The Bradykinin B2 receptor is required for full expression of renal COX-2 and renin. (Imig JD, Zhao X, Orengo SR, Dipp S, El-Dahr SS) Peptides 2003 Aug;24(8):1141-7 PMID 14612184
  • 12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. (Yiu SS, Zhao X, Inscho EW, Imig JD) J Lipid Res 2003 Dec;44(12):2391-9 PMID 12951362
  • Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. (Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM) Hypertension 2003 Oct;42(4):594-9 PMID 12939236
  • Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. (Zhao X, Pollock DM, Zeldin DC, Imig JD) Hypertension 2003 Oct;42(4):775-80 PMID 12900436
  • Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. (Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD) Hypertension 2003 Mar;41(3 Pt 2):709-14 PMID 12623984
  • Kidney CYP450 enzymes: biological actions beyond drug metabolism. (Zhao X, Imig JD) Curr Drug Metab 2003 Feb;4(1):73-84 PMID 12570747
  • Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. (Imig JD, Breyer MD, Breyer RM) Am J Physiol Renal Physiol 2002 Sep;283(3):F415-22 PMID 12167591
  • Adaptations of the renal microcirculation to hypertension. (Imig JD, Inscho EW) Microcirculation 2002;9(4):315-28 PMID 12152107
  • Renal AT1 receptor protein expression during the early stage of diabetes mellitus. (Harrison-Bernard LM, Imig JD, Carmines PK) Int J Exp Diabetes Res 2002 Apr-Jun;3(2):97-108 PMID 11991202
  • Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. (Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD) Hypertension 2002 Feb;39(2 Pt 2):690-4 PMID 11882632
  • Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. (Zhuo JL, Imig JD, Hammond TG, Orengo S, Benes E, Navar LG) Hypertension 2002 Jan;39(1):116-21 PMID 11799089
  • The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. (Zhao X, Inscho EW, Bondlela M, Falck JR, Imig JD) Am J Physiol Heart Circ Physiol 2001 Nov;281(5):H2089-96 PMID 11668070
  • Postglomerular vasoconstriction to angiotensin II and norepinephrine depends on intracellular calcium release. (Imig JD, Cook AK, Inscho EW) Gen Pharmacol 2000 Jun;34(6):409-15 PMID 11483290
  • Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. (Imig JD, Falck JR, Wei S, Capdevila JH) J Vasc Res 2001 May-Jun;38(3):247-55 PMID 11399897
  • Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. (Imig JD, Zhao X, Falck JR, Wei S, Capdevila JH) J Hypertens 2001 May;19(5):983-92 PMID 11393683
  • Unraveling the Mystery of Goldblatt Hypertension. (Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD) News Physiol Sci 1998 Aug;13():170-176 PMID 11390784
  • Calcium signaling pathways utilized by P2X receptors in freshly isolated preglomerular MVSMC. (White SM, Imig JD, Kim TT, Hauschild BC, Inscho EW) Am J Physiol Renal Physiol 2001 Jun;280(6):F1054-61 PMID 11352845
  • Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. (Holla VR, Adas F, Imig JD, Zhao X, Price E Jr, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, Capdevila JH) Proc Natl Acad Sci U S A 2001 Apr 24;98(9):5211-6 PMID 11320253
  • Epoxygenase metabolites. Epithelial and vascular actions. (Imig JD) Mol Biotechnol 2000 Nov;16(3):233-51 PMID 11252808
  • Measurement of Renal Tubular Angiotensin II. (Imig JD, Gabriel Navar L) Methods Mol Med 2001;51:427-34 PMID 21331734
  • Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. (Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG, Burns KD) Kidney Int 2000 Dec;58(6):2320-30 PMID 11115066
  • Eicosanoid regulation of the renal vasculature. (Imig JD) Am J Physiol Renal Physiol 2000 Dec;279(6):F965-81 PMID 11097615
  • Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. (Imig JD) Am J Hypertens 2000 Jul;13(7):810-8 PMID 10933574
  • Renal responses to AT1 receptor blockade. (Navar LG, Harrison-Bernard LM, Imig JD, Cervenka L, Mitchell KD) Am J Hypertens 2000 Jan;13(1 Pt 2):45S-54S PMID 10678288
  • Nitric oxide-angiotensin II interactions in angiotensin II-dependent hypertension. (Navar LG, Ichihara A, Chin SY, Imig JD) Acta Physiol Scand 2000 Jan;168(1):139-47 PMID 10691792
  • Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. (Imig JD, Pham BT, LeBlanc EA, Reddy KM, Falck JR, Inscho EW) Hypertension 2000 Jan;35(1 Pt 2):307-12 PMID 10642316
  • Endothelin-mediated calcium signaling in preglomerular smooth muscle cells. (Schroeder AC, Imig JD, LeBlanc EA, Pham BT, Pollock DM, Inscho EW) Hypertension 2000 Jan;35(1 Pt 2):280-6 PMID 10642311
  • Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure. (Ichihara A, Imig JD, Navar LG) Hypertension 1999 Oct;34(4 Pt 2):843-7 PMID 10523371
  • Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. (Imig JD, Falck JR, Inscho EW) Br J Pharmacol 1999 Jul;127(6):1399-405 PMID 10455289
  • Early onset salt-sensitive hypertension in bradykinin B(2) receptor null mice. (Cervenka L, Harrison-Bernard LM, Dipp S, Primrose G, Imig JD, El-Dahr SS) Hypertension 1999 Aug;34(2):176-80 PMID 10454437
  • Renal endosomes contain angiotensin peptides, converting enzyme, and AT(1A) receptors. (Imig JD, Navar GL, Zou LX, O'Reilly KC, Allen PL, Kaysen JH, Hammond TG, Navar LG) Am J Physiol 1999 Aug;277(2 Pt 2):F303-11 PMID 10444586
  • Epoxyeicosatrienoic acids. Biosynthesis, regulation, and actions. (Imig JD) Methods Mol Biol 1999;120:173-92 PMID 10343317
  • Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. (Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD) J Am Soc Nephrol 1999 Apr;10 Suppl 12:S266-72 PMID 10201881
  • ATP-mediated Ca2+ signaling in preglomerular smooth muscle cells. (Inscho EW, Schroeder AC, Deichmann PC, Imig JD) Am J Physiol 1999 Mar;276(3 Pt 2):F450-6 PMID 10070169
  • Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A. (Imig JD, Inscho EW, Deichmann PC, Reddy KM, Falck JR) Hypertension 1999 Jan;33(1 Pt 2):408-13 PMID 9931138
  • Neuronal nitric oxide synthase-dependent afferent arteriolar function in angiotensin II-induced hypertension. (Ichihara A, Imig JD, Navar LG) Hypertension 1999 Jan;33(1 Pt 2):462-6 PMID 9931148
  • Purinoceptor-mediated calcium signaling in preglomerular smooth muscle cells. (Inscho EW, LeBlanc EA, Pham BT, White SM, Imig JD) Hypertension 1999 Jan;33(1 Pt 2):195-200 PMID 9931104
  • Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats. (Inscho EW, Imig JD, Deichmann PC, Cook AK) J Am Soc Nephrol 1999 Jan;10 Suppl 11:S178-83 PMID 9892160
  • Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. (Ichihara A, Imig JD, Inscho EW, Navar LG) Am J Physiol 1998 Oct;275(4 Pt 2):F605-12 PMID 9755132
  • Heterogeneous activation mechanisms in the renal microvasculature. (Navar LG, Inscho EW, Imig JD, Mitchell KD) Kidney Int Suppl 1998 Sep;67:S17-21 PMID 9736247
  • Renal uptake of circulating angiotensin II in Val5-angiotensin II infused rats is mediated by AT1 receptor. (Zou LX, Imig JD, Hymel A, Navar LG) Am J Hypertens 1998 May;11(5):570-8 PMID 9633793
  • Interactive nitric oxide-angiotensin II influences on renal microcirculation in angiotensin II-induced hypertension. (Ichihara A, Imig JD, Inscho EW, Navar LG) Hypertension 1998 Jun;31(6):1255-60 PMID 9622138
  • Neuronal nitric oxide synthase modulates rat renal microvascular function. (Ichihara A, Inscho EW, Imig JD, Navar LG) Am J Physiol 1998 Mar;274(3 Pt 2):F516-24 PMID 9530268
  • Calcium mobilization contributes to pressure-mediated afferent arteriolar vasoconstriction. (Inscho EW, Cook AK, Mui V, Imig JD) Hypertension 1998 Jan;31(1 Pt 2):421-8 PMID 9453339
  • Intrarenal production of angiotensin II. (Navar LG, Imig JD, Zou L, Wang CT) Semin Nephrol 1997 Sep;17(5):412-22 PMID 9316209
  • Afferent arteriolar responses to ANG II involve activation of PLA2 and modulation by lipoxygenase and P-450 pathways. (Imig JD, Deichmann PC) Am J Physiol 1997 Aug;273(2 Pt 2):F274-82 PMID 9277588
  • Agonist-induced calcium regulation in freshly isolated renal microvascular smooth muscle cells. (Inscho EW, Mason MJ, Schroeder AC, Deichmann PC, Stiegler KD, Imig JD) J Am Soc Nephrol 1997 Apr;8(4):569-79 PMID 10495786
  • Effects of phospholipase A2, 12-lipoxygenase, and cyclooxygenase inhibitors in the feline pulmonary bed. (Kaye AD, Nossaman BD, Smith DE, Ibrahim IN, Imig JD, Kadowitz PJ) Am J Physiol 1997 Apr;272(4 Pt 1):L573-9 PMID 9142927
  • Role of renal nerves in afferent arteriolar reactivity in angiotensin-induced hypertension. (Ichihara A, Inscho EW, Imig JD, Michel RE, Navar LG) Hypertension 1997 Jan;29(1 Pt 2):442-9 PMID 9039140
  • Afferent and efferent arteriolar vasoconstriction to angiotensin II and norepinephrine involves release of Ca2+ from intracellular stores. (Inscho EW, Imig JD, Cook AK) Hypertension 1997 Jan;29(1 Pt 2):222-7 PMID 9039106
  • Actions of epoxygenase metabolites on the preglomerular vasculature. (Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR) J Am Soc Nephrol 1996 Nov;7(11):2364-70 PMID 8959626
  • Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. (Zou LX, Imig JD, von Thun AM, Hymel A, Ono H, Navar LG) Hypertension 1996 Oct;28(4):669-77 PMID 8843896
  • Identification of a putative microvascular oxygen sensor. (Harder DR, Narayanan J, Birks EK, Liard JF, Imig JD, Lombard JH, Lange AR, Roman RJ) Circ Res 1996 Jul;79(1):54-61 PMID 8925569
  • Afferent arteriolar response to arachidonic acid: involvement of metabolic pathways. (Imig JD, Navar LG) Am J Physiol 1996 Jul;271(1 Pt 2):F87-93 PMID 8760247
  • Paracrine regulation of the renal microcirculation. (Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD) Physiol Rev 1996 Apr;76(2):425-536 PMID 8618962
  • Renal accumulation of circulating angiotensin II in angiotensin II-infused rats. (Zou LX, Hymel A, Imig JD, Navar LG) Hypertension 1996 Mar;27(3 Pt 2):658-62 PMID 8613220
  • Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. (Imig JD, Zou AP, Stec DE, Harder DR, Falck JR, Roman RJ) Am J Physiol 1996 Jan;270(1 Pt 2):R217-27 PMID 8769805
  • Effect of P-450 omega-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. (Zou AP, Imig JD, Ortiz de Montellano PR, Sui Z, Falck JR, Roman RJ) Am J Physiol 1994 Jun;266(6 Pt 2):F934-41 PMID 8023972
  • Cytochrome P-450 inhibitors alter afferent arteriolar responses to elevations in pressure. (Imig JD, Zou AP, Ortiz de Montellano PR, Sui Z, Roman RJ) Am J Physiol 1994 May;266(5 Pt 2):H1879-85 PMID 8203587
  • Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. (Zou AP, Imig JD, Kaldunski M, Ortiz de Montellano PR, Sui Z, Roman RJ) Am J Physiol 1994 Feb;266(2 Pt 2):F275-82 PMID 8141328
  • Elevated renovascular tone in young spontaneously hypertensive rats. Role of cytochrome P-450. (Imig JD, Falck JR, Gebremedhin D, Harder DR, Roman RJ) Hypertension 1993 Sep;22(3):357-64 PMID 8349328
  • Chloride alters renal blood flow autoregulation in deoxycorticosterone-treated rats. (Imig JD, Passmore JC, Anderson GL, Jimenez AE) J Lab Clin Med 1993 Apr;121(4):608-13 PMID 8454943
  • Role of cytochrome P-450 in elevating renal vascular tone in spontaneously hypertensive rats. (Gebremedhin D, Ma YH, Imig JD, Harder DR, Roman RJ) J Vasc Res 1993 Jan-Feb;30(1):53-60 PMID 8435472
  • Modulation of vascular tone in renal microcirculation by erythrocytes: role of EDRF. (Imig JD, Gebremedhin D, Harder DR, Roman RJ) Am J Physiol 1993 Jan;264(1 Pt 2):H190-5 PMID 8430846
  • Nitric oxide modulates vascular tone in preglomerular arterioles. (Imig JD, Roman RJ) Hypertension 1992 Jun;19(6 Pt 2):770-4 PMID 1592479
  • Small artery resistance increases during the development of renal hypertension. (Imig JD, Anderson GL) Hypertension 1991 Mar;17(3):317-22 PMID 1999362
  • Grants and Awards

  • P450 Monooxygenases and Renal Vascular Regulation (#9208004 07/01/2013 - 06/30/2014) Sponsor: Vanderbilt University
  • Identification of EET Receptors (#9208102 07/01/2013 - 06/30/2015) Sponsor: American Heart Association - Midwest Affiliate
  • Development of Novel EET Analog Based Therapy for Cardiovascular Diseases (#9207268 01/01/2012 - 12/31/2013) Sponsor: American Heart Association - Midwest Affiliate
  • Epoxyeicosanoids and Renal Vascular Function in Obesity and Hypertension (#9205111 06/01/2008 - 05/31/2013) Sponsor: NIH Heart Lung and Blood Institute
  • Advancing New Discoveries in Translational Research Through the Collaborative and Pilot Studies Program (#9520196 04/01/2011 - 03/31/2016) PI of Therapeutic Targeting of Epoxyeicosanoids for Renal and Cardiovascular Diseases (#5520199)
  • Advancing New Discoveries in Translational Research Through the Collaborative and Pilot Studies Program (#9520196 04/01/2011 - 03/31/2016) PI of Novel Small Molecules to Treat Radiation Injury (#5520282)